Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 5/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 3/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | LIPC | P11150 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4573181 | 0.86 | MERTK (0.37) | PTGS2SCN9AMAP4K4CNR2 | |
| SCHEMBL5108200 | 0.85 | CA1 (0.41) | CA9CA2CA1PTGS1PTGS2 | |
| SCHEMBL4573278 | 0.84 | MAP4K4 (0.42) | MAPTRXFP1MAP4K4 | |
| SCHEMBL5115054 | 0.83 | CA2 (0.53) | CA9CA2CA1PTGS1PTGS2 | |
| SCHEMBL5114812 | 0.83 | CA2 (0.53) | CA9CA2CA1PTGS1PTGS2 | |
| SCHEMBL5123059 | 0.83 | KCNH3 (0.46) | PDE5AMAPTMAP4K4CNR2 | |
| SCHEMBL4573310 | 0.82 | MAP4K4 (0.36) | PDE5ASCN9AMAP4K4CNR2 | |
| SCHEMBL5123850 | 0.82 | MAPT (0.43) | PTGS1PTGS2MAPT | |
| SCHEMBL5108425 | 0.81 | ACP1 (0.43) | MAPTCNR2 | |
| SCHEMBL5123349 | 0.80 | PTGS2 (0.55) | CA9CA2CA1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PNP | CA9 4708/4885CA2 4444/4885CA1 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.